Xbrane Biopharma AB (OSTO:XBRANE) Total Stockholders Equity : kr394.1 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Total Stockholders Equity?

Xbrane Biopharma AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr394.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Xbrane Biopharma AB's Book Value per Share for the quarter that ended in Mar. 2024 was kr0.26. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Xbrane Biopharma AB's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.59.

Xbrane Biopharma AB Total Stockholders Equity Historical Data

The historical data trend for Xbrane Biopharma AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Total Stockholders Equity Chart

Xbrane Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

159.35

257.71

431.74

424.89

171.34

Xbrane Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															367.41	399.99	331.26	171.34	394.12

Xbrane Biopharma AB (OSTO:XBRANE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Xbrane Biopharma AB's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(394.119	-	0)	/	1529.48
	=	0.26

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Xbrane Biopharma AB's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(96.431	+	134.338)	/	394.119
	=	0.59

Xbrane Biopharma AB Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

7XB:Germany

Address

Retzius vag 8, Solna, SWE, 171 65

Website

https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines